Two Sigma Advisers LP Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Two Sigma Advisers LP grew its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 2.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 381,197 shares of the biotechnology company’s stock after purchasing an additional 8,396 shares during the period. Two Sigma Advisers LP owned approximately 0.06% of OPKO Health worth $560,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Capital Advisors Inc. OK bought a new stake in shares of OPKO Health in the 4th quarter worth about $220,000. Ieq Capital LLC acquired a new position in OPKO Health in the fourth quarter worth $52,000. Y Intercept Hong Kong Ltd bought a new stake in shares of OPKO Health during the 4th quarter valued at about $102,000. Raymond James Financial Inc. bought a new stake in shares of OPKO Health during the 4th quarter valued at about $221,000. Finally, Essential Planning LLC. bought a new stake in shares of OPKO Health during the 4th quarter valued at about $506,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on OPK shares. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a report on Friday, April 25th. They set a “neutral” rating for the company. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Thursday, May 1st. Finally, Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $2.75.

OPKO Health Price Performance

NASDAQ OPK opened at $1.38 on Wednesday. The stock’s 50-day moving average price is $1.40 and its two-hundred day moving average price is $1.54. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.09 billion, a PE ratio of -7.26 and a beta of 1.42. OPKO Health, Inc. has a 1 year low of $1.19 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same quarter in the prior year, the company earned ($0.12) EPS. OPKO Health’s revenue for the quarter was down 13.7% on a year-over-year basis. On average, analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the stock in a transaction on Friday, March 28th. The shares were bought at an average price of $1.70 per share, for a total transaction of $255,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 213,651,448 shares in the company, valued at approximately $363,207,461.60. This trade represents a 0.07% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have bought 700,000 shares of company stock worth $1,123,000. Insiders own 49.69% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.